TY - JOUR AU - Lin, T. AU - Liu, Z. AU - Liu, L. PY - 2017 DA - 2017// TI - Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma JO - Oncol Lett VL - 13 UR - https://doi.org/10.3892/ol.2017.5926 DO - 10.3892/ol.2017.5926 ID - Lin2017 ER - TY - JOUR AU - Niegisch, G. AU - Gerullis, H. AU - Lin, S. W. PY - 2018 DA - 2018// TI - A real-world data study to evaluate treatment patterns, clinical characteristics and survival outcomes for first- and second-line treatment in locally advanced and metastatic Urothelial Cancer patients in Germany JO - J Cancer VL - 9 UR - https://doi.org/10.7150/jca.23162 DO - 10.7150/jca.23162 ID - Niegisch2018 ER - TY - JOUR AU - Nakagawa, T. AU - Taguchi, S. AU - Kanatani, A. PY - 2017 DA - 2017// TI - Oncologic outcome of Metastasectomy for Urothelial carcinoma: who is the best candidate? JO - Ann Surg Oncol VL - 24 UR - https://doi.org/10.1245/s10434-017-5970-8 DO - 10.1245/s10434-017-5970-8 ID - Nakagawa2017 ER - TY - JOUR AU - Wu, X. J. AU - Zhi, Y. AU - He, P. PY - 2016 DA - 2016// TI - Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis JO - Onco Targets Ther VL - 9 ID - Wu2016 ER - TY - JOUR AU - Hsieh, M. C. AU - Huang, C. H. AU - Chiang, P. H. AU - Chen, Y. Y. AU - Tang, Y. AU - Su, Y. L. PY - 2016 DA - 2016// TI - Tailored selection of first-line cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma of bladder JO - J Cancer VL - 7 UR - https://doi.org/10.7150/jca.15213 DO - 10.7150/jca.15213 ID - Hsieh2016 ER - TY - JOUR AU - Oing, C. AU - Rink, M. AU - Oechsle, K. AU - Seidel, C. AU - Amsberg, G. AU - Bokemeyer, C. PY - 2016 DA - 2016// TI - Second line chemotherapy for advanced and metastatic Urothelial carcinoma: Vinflunine and beyond-a comprehensive review of the current literature JO - J Urol VL - 195 UR - https://doi.org/10.1016/j.juro.2015.06.115 DO - 10.1016/j.juro.2015.06.115 ID - Oing2016 ER - TY - JOUR AU - Zachos, I. AU - Konstantinopoulos, P. A. AU - Tzortzis, V. PY - 2010 DA - 2010// TI - Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise JO - Expert Opin Investig Drugs VL - 19 UR - https://doi.org/10.1517/13543784.2010.496450 DO - 10.1517/13543784.2010.496450 ID - Zachos2010 ER - TY - JOUR AU - Vos, F. Y. AU - Wit, R. PY - 2010 DA - 2010// TI - Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy JO - Ther Adv Med Oncol VL - 2 UR - https://doi.org/10.1177/1758834010376185 DO - 10.1177/1758834010376185 ID - Vos2010 ER - TY - JOUR AU - Sella, A. AU - Kovel, S. PY - 2012 DA - 2012// TI - Combination of gemcitabine and carboplatin in urothelial cancer patients unfit for cisplatin due to impaired renal or cardiac function JO - Int Braz J Urol VL - 38 UR - https://doi.org/10.1590/S1677-55382012000100007 DO - 10.1590/S1677-55382012000100007 ID - Sella2012 ER - TY - JOUR AU - Ciccarese, C. AU - Iacovelli, R. AU - Bria, E. PY - 2019 DA - 2019// TI - Second-line therapy for metastatic urothelial carcinoma: defining the best treatment option among immunotherapy, chemotherapy, and antiangiogenic targeted therapies. A systematic review and meta-analysis JO - Semin Oncol VL - 46 UR - https://doi.org/10.1053/j.seminoncol.2019.01.001 DO - 10.1053/j.seminoncol.2019.01.001 ID - Ciccarese2019 ER - TY - JOUR AU - Nunno, V. AU - Luca, E. AU - Buttigliero, C. PY - 2018 DA - 2018// TI - Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: a systematic review and meta-analysis JO - Crit Rev Oncol Hematol VL - 129 UR - https://doi.org/10.1016/j.critrevonc.2018.07.004 DO - 10.1016/j.critrevonc.2018.07.004 ID - Nunno2018 ER - TY - JOUR AU - Raggi, D. AU - Miceli, R. AU - Sonpavde, G. PY - 2016 DA - 2016// TI - Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv509 DO - 10.1093/annonc/mdv509 ID - Raggi2016 ER - TY - JOUR AU - Hutton, B. AU - Salanti, G. AU - Caldwell, D. M. PY - 2015 DA - 2015// TI - The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations JO - Ann Intern Med VL - 162 UR - https://doi.org/10.7326/M14-2385 DO - 10.7326/M14-2385 ID - Hutton2015 ER - TY - JOUR AU - Higgins, J. P. AU - Altman, D. G. AU - Gotzsche, P. C. PY - 2011 DA - 2011// TI - The Cochrane Collaboration's tool for assessing risk of bias in randomised trials JO - BMJ. VL - 343 UR - https://doi.org/10.1136/bmj.d5928 DO - 10.1136/bmj.d5928 ID - Higgins2011 ER - TY - JOUR AU - Greco, T. AU - Edefonti, V. AU - Biondi-Zoccai, G. PY - 2015 DA - 2015// TI - A multilevel approach to network meta-analysis within a frequentist framework JO - Contemp Clin Trials VL - 42 UR - https://doi.org/10.1016/j.cct.2015.03.005 DO - 10.1016/j.cct.2015.03.005 ID - Greco2015 ER - TY - JOUR AU - Li, D. AU - Wang, T. AU - Shen, S. PY - 2015 DA - 2015// TI - Effects of Fluroquinolones in newly diagnosed, sputum-positive tuberculosis therapy: a systematic review and network meta-analysis JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0145066 DO - 10.1371/journal.pone.0145066 ID - Li2015 ER - TY - JOUR AU - Trinquart, L. AU - Chatellier, G. AU - Ravaud, P. PY - 2012 DA - 2012// TI - Adjustment for reporting bias in network meta-analysis of antidepressant trials JO - BMC Med Res Methodol VL - 12 UR - https://doi.org/10.1186/1471-2288-12-150 DO - 10.1186/1471-2288-12-150 ID - Trinquart2012 ER - TY - JOUR AU - Fradet, Y. AU - Bellmunt, J. AU - Vaughn, D. J. AU - Lee, J. L. AU - Fong, L. AU - Vogelzang, N. J. AU - Climent, M. A. AU - Petrylak, D. P. AU - Choueiri, T. K. AU - Necchi, A. AU - Gerritsen, W. AU - Gurney, H. AU - Quinn, D. I. AU - Culine, S. AU - Sternberg, C. N. AU - Nam, K. AU - Frenkl, T. L. AU - Perini, R. F. AU - de Wit, R. AU - Bajorin, D. F. PY - 2019 DA - 2019// TI - Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up JO - Annals of Oncology VL - 30 UR - https://doi.org/10.1093/annonc/mdz127 DO - 10.1093/annonc/mdz127 ID - Fradet2019 ER - TY - JOUR AU - Rosenberg, J. E. AU - Hahn, N. M. AU - Regan, M. M. PY - 2018 DA - 2018// TI - Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2) JO - Br J Cancer VL - 118 UR - https://doi.org/10.1038/s41416-018-0087-9 DO - 10.1038/s41416-018-0087-9 ID - Rosenberg2018 ER - TY - JOUR AU - Powles, T. AU - Duran, I. AU - Heijden, M. S. PY - 2018 DA - 2018// TI - Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial JO - Lancet. VL - 391 UR - https://doi.org/10.1016/S0140-6736(17)33297-X DO - 10.1016/S0140-6736(17)33297-X ID - Powles2018 ER - TY - JOUR AU - Petrylak, D. P. AU - Wit, R. AU - Chi, K. N. PY - 2017 DA - 2017// TI - Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial JO - Lancet. VL - 390 UR - https://doi.org/10.1016/S0140-6736(17)32365-6 DO - 10.1016/S0140-6736(17)32365-6 ID - Petrylak2017 ER - TY - JOUR AU - Jones, R. J. AU - Hussain, S. A. AU - Protheroe, A. S. PY - 2017 DA - 2017// TI - Randomized phase II study investigating Pazopanib versus weekly paclitaxel in relapsed or progressive Urothelial Cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2016.70.7828 DO - 10.1200/JCO.2016.70.7828 ID - Jones2017 ER - TY - JOUR AU - Bellmunt, J. AU - Kerst, J. M. AU - Vazquez, F. PY - 2017 DA - 2017// TI - A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN) JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx186 DO - 10.1093/annonc/mdx186 ID - Bellmunt2017 ER - TY - JOUR AU - Petrylak, D. P. AU - Tagawa, S. T. AU - Kohli, M. PY - 2016 DA - 2016// TI - Docetaxel as Monotherapy or combined with Ramucirumab or Icrucumab in second-line treatment for locally advanced or metastatic Urothelial carcinoma: an open-label, three-arm, randomized controlled phase II trial JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.65.0218 DO - 10.1200/JCO.2015.65.0218 ID - Petrylak2016 ER - TY - JOUR AU - Santis, M. AU - Wiechno, P. J. AU - Bellmunt, J. PY - 2016 DA - 2016// TI - Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1) JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdv609 DO - 10.1093/annonc/mdv609 ID - Santis2016 ER - TY - JOUR AU - Noguchi, M. AU - Matsumoto, K. AU - Uemura, H. PY - 2016 DA - 2016// TI - An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder Cancer that progressed after platinum-based chemotherapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-1265 DO - 10.1158/1078-0432.CCR-15-1265 ID - Noguchi2016 ER - TY - JOUR AU - Bellmunt, J. AU - Fougeray, R. AU - Rosenberg, J. E. PY - 2013 DA - 2013// TI - Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy JO - Ann Oncol VL - 24 UR - https://doi.org/10.1093/annonc/mdt007 DO - 10.1093/annonc/mdt007 ID - Bellmunt2013 ER - TY - JOUR AU - Choueiri, T. K. AU - Ross, R. W. AU - Jacobus, S. PY - 2012 DA - 2012// TI - Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.7002 DO - 10.1200/JCO.2011.37.7002 ID - Choueiri2012 ER - TY - JOUR AU - Santis, M. AU - Bellmunt, J. AU - Mead, G. PY - 2012 DA - 2012// TI - Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986 JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.37.3571 DO - 10.1200/JCO.2011.37.3571 ID - Santis2012 ER - TY - JOUR AU - Culine, S. AU - Flechon, A. AU - Guillot, A. PY - 2011 DA - 2011// TI - Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French genitourinary tumor group (GETUG V01) JO - Eur Urol VL - 60 UR - https://doi.org/10.1016/j.eururo.2011.08.072 DO - 10.1016/j.eururo.2011.08.072 ID - Culine2011 ER - TY - JOUR AU - Bellmunt, J. AU - Wit, R. AU - Vaughn, D. J. PY - 2017 DA - 2017// TI - Pembrolizumab as second-line therapy for advanced Urothelial carcinoma JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMoa1613683 DO - 10.1056/NEJMoa1613683 ID - Bellmunt2017 ER - TY - JOUR AU - Xu, C. AU - Chen, Y. P. AU - Du, X. J. PY - 2018 DA - 2018// TI - Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis JO - BMJ. VL - 363 UR - https://doi.org/10.1136/bmj.k4226 DO - 10.1136/bmj.k4226 ID - Xu2018 ER - TY - JOUR AU - Sato, M. AU - Tamura, R. AU - Tamura, H. PY - 2019 DA - 2019// TI - Analysis of tumor angiogenesis and immune microenvironment in non-functional pituitary endocrine tumors JO - J Clin Med VL - 8 UR - https://doi.org/10.3390/jcm8050695 DO - 10.3390/jcm8050695 ID - Sato2019 ER - TY - JOUR AU - Jiang, F. AU - Yu, W. AU - Zeng, F. PY - 2019 DA - 2019// TI - PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma JO - BMC Cancer VL - 19 UR - https://doi.org/10.1186/s12885-019-5689-y DO - 10.1186/s12885-019-5689-y ID - Jiang2019 ER - TY - JOUR AU - Incorvaia, L. AU - Badalamenti, G. AU - Rinaldi, G. PY - 2019 DA - 2019// TI - Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? JO - Ther Adv Med Oncol VL - 11 UR - https://doi.org/10.1177/1758835919848872 DO - 10.1177/1758835919848872 ID - Incorvaia2019 ER - TY - JOUR AU - Wei, Y. AU - Zhao, Q. AU - Gao, Z. PY - 2019 DA - 2019// TI - The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy JO - J Clin Invest VL - 129 UR - https://doi.org/10.1172/JCI127726 DO - 10.1172/JCI127726 ID - Wei2019 ER - TY - JOUR AU - Yang, S. AU - Zhang, Z. AU - Wang, Q. PY - 2019 DA - 2019// TI - Emerging therapies for small cell lung cancer JO - J Hematol Oncol VL - 12 UR - https://doi.org/10.1186/s13045-019-0736-3 DO - 10.1186/s13045-019-0736-3 ID - Yang2019 ER - TY - JOUR AU - Yu, S. S. AU - Dorff, T. B. AU - Ballas, L. K. AU - Sadeghi, S. AU - Skinner, E. C. AU - Quinn, D. I. PY - 2017 DA - 2017// TI - Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease JO - Clin Adv Hematol Oncol VL - 15 ID - Yu2017 ER - TY - JOUR AU - Kim, J. AU - Cho, J. AU - Lee, M. H. AU - Lim, J. H. PY - 2018 DA - 2018// TI - Relative efficacy of checkpoint inhibitors for advanced NSCLC according to programmed death-Ligand-1 expression: a systematic review and network meta-analysis JO - Sci Rep VL - 8 UR - https://doi.org/10.1038/s41598-018-30277-0 DO - 10.1038/s41598-018-30277-0 ID - Kim2018 ER - TY - JOUR AU - Yamaguchi, K. AU - Fujitani, K. AU - Nagashima, F. PY - 2018 DA - 2018// TI - Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study JO - Gastric Cancer VL - 21 UR - https://doi.org/10.1007/s10120-018-0811-4 DO - 10.1007/s10120-018-0811-4 ID - Yamaguchi2018 ER - TY - JOUR AU - Yoon, H. H. AU - Bendell, J. C. AU - Braiteh, F. S. PY - 2016 DA - 2016// TI - Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter phase II trial JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw423 DO - 10.1093/annonc/mdw423 ID - Yoon2016 ER - TY - JOUR AU - Perol, M. AU - Ciuleanu, T. E. AU - Arrieta, O. PY - 2016 DA - 2016// TI - Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy JO - Lung Cancer VL - 93 UR - https://doi.org/10.1016/j.lungcan.2016.01.007 DO - 10.1016/j.lungcan.2016.01.007 ID - Perol2016 ER -